---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005094"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:18:56.257193+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports Q4 2022 net loss of $45M; paltusotine Phase 3 data expected 3Q23 and 1Q24

## Summary
- Net loss $45.0M for Q4 2022 vs $30.8M in Q4 2021; full-year net loss $163.9M vs $107.6M.
- R&D expenses $37.0M in Q4 2022, up from $24.6M; full-year $130.2M vs $84.3M.
- Cash, equivalents, and investments $334.4M as of Dec 31, 2022; company expects runway through 2024.
- Paltusotine Phase 3 PATHFNDR-1 topline data expected 3Q23; PATHFNDR-2 data now expected 1Q24.
- NDA submission for paltusotine in acromegaly planned for 2024 pending positive Phase 3 results.

## SEC filing metadata
- accession: 0000950170-23-005094
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/crnx-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005094
- JSON: https://secwatch.observer/filing/0000950170-23-005094.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005094.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.